SUCLA2-USP10 interaction rather than SUCLA2 alone correlates with metastasis in breast cancer patients
Computational Biomedicine · 2026
DOI: 10.70401/cbm.2026.0022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Computational Biomedicine, 2026. Verfasst von Xinwei He und 2 weiteren Autor:innen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Aims
Translating pre-clinical findings into clinical evidence is essential for cancer research. Although succinyl-CoA ligase ADP-forming subunit beta (SUCLA2) has been implicated in metastasis through stress granule assembly in pre-clinical models, direct clinical evidence linking SUCLA2, alone or in interaction with stress granule components such as ubiquitin-specific peptidase 10 (USP10), to distant metastasis-free survival (DMFS) remains limited. This study aimed to evaluate whether the SUCLA2-USP10 interaction correlates with breast cancer DMFS and whether treatment modifies this association.
Methods
We analyzed four independent breast cancer cohorts with DMFS data (GSE17705, GSE45255, GSE7390, and GSE11121). Patients were stratified into four subgroups based on median SUCLA2 and USP10 expression levels: low-SUCLA2/low-USP10 (LL), low-SUCLA2/high-USP10 (LH), high-SUCLA2/low-USP10 (HL), and high-SUCLA2/high-USP10 (HH). Stratified Cox regression was applied, with cohort as the stratification factor, to examine whether the prognostic impact of these subgroups differed between treated and untreated patients.
Results
A significant interaction was observed between treatment status and SUCLA2-USP10 subgroup membership, specifically for the LH subgroup (p = 0.00038). In untreated patients, the LH subgroup exhibited a significantly higher risk for DMFS (HR = 2.45), whereas in treated patients, this elevated risk was completely abrogated (HR = 0.71). Neither SUCLA2 nor USP10 alone showed a consistent association with DMFS across the four cohorts.
Conclusion
These findings provide clinical evidence that the SUCLA2-USP10 interaction, rather than either factor alone, correlates with breast cancer DMFS. The treatment-modulated risk reversal observed in the LH subgroup supports the development of anti-metastatic strategies targeting this interaction.
Zitieren
APA
He, X., Shao, Y., & Sun, X. (2026). SUCLA2-USP10 interaction rather than SUCLA2 alone correlates with metastasis in breast cancer patients. Computational Biomedicine. https://doi.org/10.70401/cbm.2026.0022
Vancouver
He X, Shao Y, Sun X. SUCLA2-USP10 interaction rather than SUCLA2 alone correlates with metastasis in breast cancer patients. Computational Biomedicine. 2026. doi:10.70401/cbm.2026.0022
BibTeX
@article{He2026,
author = {He, Xinwei and Shao, Yongzhao and Sun, Xiaoqiang},
title = {SUCLA2-USP10 interaction rather than SUCLA2 alone correlates with metastasis in breast cancer patients},
journal = {Computational Biomedicine},
year = {2026},
doi = {10.70401/cbm.2026.0022}
}
EUVIMED